TY - JOUR
T1 - Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation
T2 - Real-World Insights From the MITRACURE International Registry
AU - MITRACURE Investigators
AU - Messika-Zeitoun, David
AU - Chu, Michael W.A.
AU - Bouchard, Denis
AU - Le Tourneau, Thierry
AU - Ternacle, Julien
AU - Demers, Philippe
AU - Guo, Linrui
AU - Fu, Angel Yi Nam
AU - Dib, Jean Claude
AU - Lam, Charmaine
AU - Sokolov, Thays
AU - Anselmi, Amedeo
AU - Tchétché, Didier
AU - Brault Meslin, Ophélie
AU - Goutondji, Ange
AU - Lavie-Badie, Yoan
AU - Seknadji, Patrick
AU - Coisne, Augustin
AU - Arangalage, Dimitri
AU - Bernard, Anne
AU - Manian, Usha
AU - Kass, Malek
AU - Fiore, Antonio
AU - Maudiere, Arnaud
AU - Bohbot, Yohann
AU - Seemann, Aurélien
AU - Hammoudi, Nadjib
AU - Bière, Loïc
AU - Leroux, Pierre Yves
AU - Forcillo, Jessica
AU - Jeu, Antoine
AU - Elegamandji, Benjamin
AU - Selton-Suty, Christine
AU - Gilard, Martine
AU - Bouleti, Claire
AU - Arshad, Omair
AU - Legare, Jean Francois
AU - Si Moussi, Thiziri
AU - Ye, Jian
AU - Sportouch, Catherine
AU - Bittira, Bindu
AU - Munte, Laura
AU - Bauer, Fabrice
AU - Ong, Geraldine
AU - Fatehi Hassanabad, Ali
AU - Bernick, Jordan
AU - Wells, George A.
AU - Gauda, Roja
AU - Iung, Bernard
AU - Kent, William D.T.
PY - 2025/9/30
Y1 - 2025/9/30
N2 - BACKGROUND: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "all-comer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. METHODS: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. RESULTS: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51-131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). CONCLUSIONS: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.
AB - BACKGROUND: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "all-comer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. METHODS: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. RESULTS: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51-131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). CONCLUSIONS: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.
KW - mitral regurgitation
KW - surgery
KW - valve repair
UR - https://www.scopus.com/pages/publications/105017651576
U2 - 10.1161/CIRCULATIONAHA.124.073674
DO - 10.1161/CIRCULATIONAHA.124.073674
M3 - Article
C2 - 40886109
AN - SCOPUS:105017651576
SN - 0009-7322
VL - 152
SP - 927
EP - 938
JO - Circulation
JF - Circulation
IS - 13
ER -